Dihydroergotamine mesylate enhances the anti-tumor effect of sorafenib in liver cancer cells
Meng He, Qiuyu Liao, Dong Liu, Xufang Dai, Meihua Shan, Mingzhen Yang, Yang Zhang, Liuyue Zhai, Lingxi Chen, Xiang Li, Mei He, Shuhui Li, An Chen, Liangbo Sun, Jiqin Lian
Topics & Concepts
SorafenibLiver cancerMedicineMAPK/ERK pathwayPharmacologyApoptosisCancerCancer cellCancer researchDihydroergotamineHepatocellular carcinomaInternal medicineChemistrySignal transductionMigraineBiochemistryCancer Mechanisms and TherapySynthesis and biological activityHistone Deacetylase Inhibitors Research